Sanford C. Bernstein Has Lowered Expectations for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price target lowered by research analysts at Sanford C. Bernstein from $56.00 to $54.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 36.64% from the company’s current price.

A number of other equities analysts have also commented on the company. BNP Paribas Exane initiated coverage on Medline in a research note on Monday, January 12th. They issued a “neutral” rating and a $38.00 price objective on the stock. Royal Bank Of Canada lifted their price objective on Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wall Street Zen raised Medline to a “hold” rating in a research note on Saturday, January 10th. Robert W. Baird started coverage on Medline in a research note on Monday, January 12th. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Morgan Stanley boosted their price target on Medline from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

Medline Trading Down 5.6%

Medline stock opened at $39.52 on Thursday. The business has a 50 day moving average of $44.40. Medline has a one year low of $34.89 and a one year high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion during the quarter. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. Equities analysts predict that Medline will post 1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medline

Several hedge funds and other institutional investors have recently modified their holdings of the company. Perigon Wealth Management LLC bought a new stake in Medline during the fourth quarter worth $211,000. SteelPeak Wealth LLC bought a new stake in Medline during the fourth quarter worth $441,000. Sound Income Strategies LLC bought a new stake in Medline during the fourth quarter worth $25,000. Massachusetts Financial Services Co. MA bought a new stake in Medline during the fourth quarter worth $429,544,000. Finally, Baillie Gifford & Co. bought a new stake in Medline during the fourth quarter worth $437,236,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported first-quarter 2026 results, with earnings per share of $0.33 beating estimates and revenue of $7.35 billion rising 10.7% year over year, supporting the case for continued business momentum. Medline Reports First Quarter 2026 Results
• Positive Sentiment: Jefferies initiated coverage with a Buy rating, adding to the bullish analyst tone around Medline and reinforcing expectations for further upside. Medline (MDLN) Receives a Buy from Jefferies
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and maintained a $55 price target, signaling confidence that Medline can recover from current levels. BTIG Research rating update
• Positive Sentiment: Bank of America Securities reiterated a Buy rating, saying margin pressures may be a near-term issue but that Medline’s growth outlook remains strong. Medline Maintained at Buy as Analyst Trims Price Target to $53
• Neutral Sentiment: Sanford C. Bernstein lowered its price target to $54 from $56 while keeping an Outperform rating, a small cautionary note that suggests the stock may face some valuation or margin headwinds. Bernstein price target update
• Neutral Sentiment: Medline also launched its AI-powered Mpower platform to improve supply chain resiliency, a strategic positive but likely not a near-term earnings driver. Medline launches AI-powered Mpower Platform

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.